You are here

Azacitadine Extends Survival in Acute Myeloid Leukemia

Hervé Dombret, MD, of Hopital Saint Louis in Paris, describes a phase 3 trial that compared azacitadine with conventional care (including intensive chemotherapy and best supportive care) in older patients with acute myeloid leukemia. The study, presented at the European Hematology Association meeting in Milan, showed a median gain of about four months in overall survival with azacitadine.

European Hematology Association, June 2014